The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...
Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against companies selling versions ...
Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo ...
Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius ...
Against a backdrop of exciting new developments in disease management, there is a need to improve access to innovation in ...
At a White House event on Nov. 6 announcing price cuts for those blockbuster weight-loss drugs, Medicare and Medicaid Administrator Mehmet Oz made an astonishing claim.
FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts ...
In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...
Findings show that inclusive attitudes among Italian oncologists coexist with clear knowledge and awareness gaps highlighting ...
Welltica+ on MSN
New drug candidate compared to existing GLP-1 treatments
A new weight-loss drug working through a different hormone pathway is raising interest among specialists who say it could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback